Skip to main content

Results of Research on Identification of Covid-19 Viruses Utilizing Advantest’s nanoSCOUTER™ Fine Particle Measurement Instrument Published in Nature Communications

Advantest WEL1100 nanoSCOUTER™ Fine Particle Measurement Instrument

Results of Research on Identification of Covid-19 Viruses Utilizing Advantest's nanoSCOUTER™ Fine Particle Measurement Instrument Published in Nature Communications

Results of Research on Identification of Covid-19 Viruses Utilizing Advantest’s nanoSCOUTER™ Fine Particle Measurement Instrument Published in Nature Communications

TOKYO, June 30, 2021 (GLOBE NEWSWIRE) — Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) has announced that the results of a clinical study on the identification of COVID-19 viruses using the company’s nanoSCOUTER™ fine particle measurement instrument were published in Nature Communications, a peer-reviewed scientific journal, on June 17th1. In the study, 100 saliva samples (50 negative for Covid-19 and 50 positive) were measured and analyzed within 5 minutes each. Sensitivity (the ability of the test to correctly identify positive samples) of 90% and specificity (the ability of the test to correctly identify negative samples) of 96% were achieved.

A research group of the Institute of Scientific and Industrial Research at Osaka University is studying virus testing methods using the AI-based particle identification system developed by Aipore Inc.2 and the nanoSCOUTER™. The method used in the just-published study identifies viral particles by passing them through a nanoscale hole, through which a microcurrent is passed, and applying AI machine-learning to the highly accurate current waveform thus obtained. The results of this research3 can be expected to facilitate immediate diagnoses in hospitals as well as viral screening for large gatherings. In addition, machine-learning can be applied to many types of viruses, enabling early detection of novel pathogens.

The nanoSCOUTER™ is a lightweight, desktop-sized fine particle measurement instrument that utilizes a precise nanopore (nanometer-scale pore) sensor module made with semiconductor manufacturing processes and Advantest’s proprietary microcurrent measurement technology. It measures the quantity and particle size of fine particles on the order of 100 nanometers, such as viruses, exosomes4, and liposomes5, with great speed and accuracy. In addition, when the nanoSCOUTER™ is used in conjunction with Aipore Inc.’s AI-based particle identification system, it is possible to quickly identify the type of particles detected. At the present time, the product is a scientific instrument, not an approved medical device.

Rapid and accurate testing methods, along with vaccines and therapeutic agents, are important measures for prevention of Covid-19 spread. Based on Advantest’s corporate mission of “enabling leading-edge technologies,” the company will strive to further develop this technology so that the nanoSCOUTER™ can contribute to solving these vital issues.

1 “Combining machine learning and nanopore construction creates an artificial intelligence nanopore for coronavirus detection,” Masateru Taniguchi, Shohei Minami, Chikako Ono, Rina Hamajima, Ayumi Morimura, Shigeto Hamaguchi, Yukihiro Akeda, Yuta Kanai, Takeshi Kobayashi, Wataru Kamitani, Yutaka Terada, Koichiro Suzuki, Nobuaki Hatori, Yoshiaki Yamagishi, Nobuei Washizu, Hiroyasu Takei, Osamu Sakamoto, Norihiko Naono, Kenji Tatematsu, Takashi Washio, Yoshiharu Matsuura, and Kazunori Tomono
https://www.nature.com/articles/s41467-021-24001-2

2 Aipore Inc. was established in 2018 as a result of the Japanese Cabinet Office’s national project “Impulsing Paradigm Change through Disruptive Technologies Program (ImPACT)”. Using Advantest’s nanoSCOUTER™, Aipore has developed a solution for AI analysis of measurement data of bioparticles such as viruses and bacteria.
https://aipore.com/

3 The Japan Agency for Medical Research and Development (AMED) subsidized this research as a part of its Reiwa 2 virus infection prevention technology development project “Research on COVID-19 test methods using nanopore technology and machine learning.”

4 Exosomes: Nano-order particles secreted from cells that contain any of various biomolecules, such as proteins or nucleic acids. Exosomes hold promise as diagnostic tools in medicine.

5 Liposomes: Closed, spherical lipid bilayers, often used as vehicles for pharmaceuticals.

About Advantest Corporation

Advantest (TSE: 6857) is the leading manufacturer of automatic test and measurement equipment used in the design and production of semiconductors for applications including 5G communications, the Internet of Things (IoT), autonomous vehicles, artificial intelligence (AI), machine learning, smart medical devices and more. Its leading-edge systems and products are integrated into the most advanced semiconductor production lines in the world. The company also conducts R&D to address emerging testing challenges and applications, produces multi-vision metrology scanning electron microscopes essential to photomask manufacturing, and offers groundbreaking 3D imaging and analysis tools. Founded in Tokyo in 1954, Advantest is a global company with facilities around the world and an international commitment to sustainable practices and social responsibility. More information is available at www.advantest.com.

ADVANTEST CORPORATION

Shin-Marunouchi Center Building
1-6-2 Marunouchi, Chiyoda-ku, Tokyo 100-0005
Tel: 03-3214-7500
Contact: Hiroki Yanagita, PR Section

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e5d9f459-637f-4ddd-8d99-d16403668dd2

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.